Anthem Biosciences FY26 PAT Up 31% to ₹5,918 Mn

Anthem Biosciences reported FY26 consolidated revenue of ₹21,243 Mn with 15.2% YoY growth and PAT of ₹5,918 Mn with 31.1% YoY growth.
Q4FY26 revenue grew 26.4% YoY to ₹6,109 Mn with PAT surging 129.8% YoY to ₹1,898 Mn, marking the highest revenue quarter ever.
The company recognized ₹244 Mn exceptional item for new labour code impact and maintained strong net cash position of ₹13,743 Mn as of March 31, 2026.
Management highlighted strong CRDMO business performance with 17.7% YoY growth and commitment to sustainable growth across all business segments.